This article was originally published in The Rose Sheet
You may also be interested in...
The Senate Appropriations Committee gives FDA a boost for fiscal 2012 that likely will stick, thanks to the recent debt ceiling compromise.
Manufacturers have different production timelines and US FDA advisory committee members worry a June strain selection may not fit the timing of COVID-19 case surges.
The Danish firm’s four key products yielded 31% sales growth in 2022, and the company is investing in the anticipated mid-year launch of an Alzheimer’s agitation indication for Rexulti.